<DOC>
	<DOCNO>NCT02581163</DOCNO>
	<brief_summary>This study provide evidence effectiveness well influence adherence treatment outcome Paritaprevir/ritonavir , Ombitasvir , +/- Dasabuvir , ( ABBVIE REGIMEN ) ± Ribavirin ( RBV ) real world set hepatitis C virus infect clinical practice population across Belgium . The study may also help identify predictive factor response important real world treatment setting . In addition , provide data impact adherence treatment outcome everyday setting , may help treat physician improve management participant care .</brief_summary>
	<brief_title>Effectiveness Paritaprevir/Ritonavir - Ombitasvir , +/- Dasabuvir , +/- Ribavirin Patients With Chronic Hepatitis C - An Observational Study Belgium</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Treatmentnaïve experience participant confirm CHC , genotype 1 4 , receive combination therapy interferonfree ABBVIE REGIMEN ± RBV accord standard care line current local label If RBV coadministered ABBVIE REGIMEN , prescribe line current local label ( special attention contraception requirement contraindication pregnancy ) Participants must sign date inform consent Participant participate intend participate concurrent interventional therapeutic trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Effectiveness</keyword>
	<keyword>Influence adherence</keyword>
</DOC>